Abcam, ab309490, Anti-ILF1 antibody [EPR27321-60] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ILF1 antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27321-60,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, ICC/IF, IHC-P, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein Interleukin Enhancer Binding Factor 1 (ILF1) also known as Nuclear Factor of Activated T-cells 90 (NF90) plays an essential role in the regulation of gene expression. ILF1 has a mass of approximately 90 kDa (kilodaltons) and is ubiquitously expressed in various tissues including the spleen and the thymus. The protein consists of two distinct ribonucleoprotein (RNP) motifs that allow it to bind RNA sequences effectively making it an important factor in controlling mRNA stability and transport.
Biological function summary
ILF1 influences several cellular processes related to RNA dynamics by engaging in RNA splicing export and translation regulation. It doesn't function alone but rather forms complexes with other proteins such as the nuclear factor 45 (NF45). Through these interactions ILF1 contributes actively to cellular stress responses influencing protein synthesis under stress conditions and aiding in regulating cytokine production.
Pathways
ILF1 intricately integrates into cellular pathways like the NF-κB signaling pathway and the T-cell receptor signaling pathway. In these contexts it interacts with proteins such as IκB kinase (IKK) and T-cell receptor-associated proteins playing a part in transcriptional regulation and immune response modulation. ILF1's involvement in these pathways highlights its importance in cellular adaptation and survival in response to external stressors and pathogens.
ILF1 is associated with conditions such as viral infections and cancer. In viral infections the protein interacts with viral RNAs impacting viral replication and host cell responses. In cancer ILF1's aberrant regulation could promote tumor progression by affecting cell proliferation and apoptosis pathways as seen in its relationship with proteins like p53 and Bcl-2. As a potential biomarker and therapeutic target understanding ILF1's pathological connections could improve diagnostic and treatment strategies for these diseases.